Correction to: Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE) (European Journal of Clinical Microbiology & Infectious Diseases, (2018), 37, 11, (2097-2106), 10.1007/s10096-018-3344-1)
- Vehreschild, M.J.G.T.
- Taori, S.
- Goldenberg, S.D.
- Thalhammer, F.
- Bouza, E.
- van Oene, J.
- Wetherill, G.
- Georgopali, A.
ISSN: 1435-4373, 0934-9723
Année de publication: 2019
Volumen: 38
Número: 1
Pages: 199
Type: Erreur
